[go: up one dir, main page]

WO2008015429A3 - Composés pharmaceutiques - Google Patents

Composés pharmaceutiques Download PDF

Info

Publication number
WO2008015429A3
WO2008015429A3 PCT/GB2007/002926 GB2007002926W WO2008015429A3 WO 2008015429 A3 WO2008015429 A3 WO 2008015429A3 GB 2007002926 W GB2007002926 W GB 2007002926W WO 2008015429 A3 WO2008015429 A3 WO 2008015429A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compounds
formula
conh2
tautomer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/002926
Other languages
English (en)
Other versions
WO2008015429A2 (fr
Inventor
Robert George Boyle
Stuart Travers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sentinel Oncology Ltd
Original Assignee
Sentinel Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0615299A external-priority patent/GB0615299D0/en
Application filed by Sentinel Oncology Ltd filed Critical Sentinel Oncology Ltd
Publication of WO2008015429A2 publication Critical patent/WO2008015429A2/fr
Publication of WO2008015429A3 publication Critical patent/WO2008015429A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé de formule (I) ou un sel, solvate ou tautomère de celui-ci, présentant une activité inhibitrice de PARP. Dans la formule (I) Q est CN ou CONH2 et est lié soit à la position 'a' ou à la position 'b' sur le même noyau benzène; Y1 est N ou N+-O-; Y2 est N ou CR3; Y3 est N ou N+-O-; à condition que lorsque Y2 est CR3, alors Y3 est N+-O-; m est 0, 1 or 2; et R1 et R2 sont tels que définis dans les revendications.
PCT/GB2007/002926 2006-08-01 2007-08-01 Composés pharmaceutiques Ceased WO2008015429A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82103106P 2006-08-01 2006-08-01
US60/821,031 2006-08-01
GB0615299A GB0615299D0 (en) 2006-08-01 2006-08-01 Pharmaceutical compounds
GB0615299.5 2006-08-01

Publications (2)

Publication Number Publication Date
WO2008015429A2 WO2008015429A2 (fr) 2008-02-07
WO2008015429A3 true WO2008015429A3 (fr) 2008-10-02

Family

ID=38692040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002926 Ceased WO2008015429A2 (fr) 2006-08-01 2007-08-01 Composés pharmaceutiques

Country Status (1)

Country Link
WO (1) WO2008015429A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017013237A1 (fr) 2015-07-23 2017-01-26 Institut Curie Utilisation d'une combinaison d'une molécule servant d'appât et d'inhibiteurs de parp pour le traitement du cancer
WO2018162439A1 (fr) 2017-03-08 2018-09-13 Onxeo Nouveau biomarqueur prédictif de la sensibilité à un traitement du cancer avec une molécule dbait
WO2019175132A1 (fr) 2018-03-13 2019-09-19 Onxeo Molécule dbait contre la résistance acquise dans le traitement du cancer
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2023019912A1 (fr) * 2021-08-16 2023-02-23 杭州瑞臻医药有限公司 Dioxyde de benzotriazine et composition pharmaceutique associée
WO2024261243A1 (fr) 2023-06-21 2024-12-26 Hemispherian As Combinaison comprenant un dérivé de désoxycytidine et un inhibiteur de parp destiné à être utilisé dans une méthode de traitement du cancer déficient en hr

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007959A1 (fr) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Derives de quinoxaline ayant une action inhibitrice sur parp
WO2003062234A1 (fr) * 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Composes de quinoxaline
EP1468688A2 (fr) * 2003-03-14 2004-10-20 Auckland Uniservices Limited Composées contenants des derivées du N-monooxyde de benzoazin et du 1,4-dioxyde de benzoazin pour le traitement du cancère

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007959A1 (fr) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Derives de quinoxaline ayant une action inhibitrice sur parp
WO2003062234A1 (fr) * 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Composes de quinoxaline
EP1468688A2 (fr) * 2003-03-14 2004-10-20 Auckland Uniservices Limited Composées contenants des derivées du N-monooxyde de benzoazin et du 1,4-dioxyde de benzoazin pour le traitement du cancère

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FUCHS T ET AL: "3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine)", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 66, no. 1, 8 December 2000 (2000-12-08), pages 107 - 114, XP002407530, ISSN: 0022-3263 *
GIBSON K H ET AL: "Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 21, 4 November 1997 (1997-11-04), pages 2723 - 2728, XP004136520, ISSN: 0960-894X *
HAY M P ET AL: "Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 46, no. 1, 2 December 2002 (2002-12-02), pages 169 - 182, XP002404330, ISSN: 0022-2623 *
HWANG JAE-TAEG ET AL: "Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: The drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 38, no. 43, 26 October 1999 (1999-10-26), pages 14248 - 14255, XP002407531, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
WO2008015429A2 (fr) 2008-02-07

Similar Documents

Publication Publication Date Title
EP1889842A4 (fr) Composé hétérocyclique
WO2006038116A3 (fr) Agents antibacteriens
WO2006053255A3 (fr) Nouveaux derives de betuline, preparation de ces derives et utilisation de ces derives
WO2008109177A3 (fr) Inhibiteurs de métalloprotéase contenant une fraction hétérocyclique
WO2007148185A3 (fr) 3-amino-pyrrolidino-4-lactames substitués
WO2005110410A3 (fr) Inhibiteurs de kinases en tant qu'agents therapeutiques
WO2006028958A3 (fr) Inhibiteurs pyridyles de la signalisation hedgehog
AU2003257822A1 (en) Heterocyclic compound having hiv integrase inhibitory activity
WO2007030582A3 (fr) Inhibiteurs d'ikur acycliques
WO2006128184A3 (fr) Inhibiteurs de metalloprotease heterobicyclique
UY30118A1 (es) Compueto amina trisustituido
HUS1400039I1 (hu) HIV Integráz inhibitor hatással rendelkezõ policiklusos karbamoilpiridon-származékok
WO2007139856A3 (fr) Inhibiteurs de métalloprotéases hétérobicycliques
WO2007025307A3 (fr) Inhibiteurs des serine proteases
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2009038064A1 (fr) Dérivé hétérocyclique à activité inhibitrice sur la 11β-hydroxystéroïde déshydrogénase de type i
EP1704856A4 (fr) Inhibiteur de proteines de la famille hsp90
WO2008156094A1 (fr) Dérivé de pyridazinone et inhibiteur de la pde le contenant comme ingrédient actif
WO2007014054A3 (fr) Inhibiteur benzenesulfonamide de recepteur de chimiokine ccr2
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
WO2008015429A3 (fr) Composés pharmaceutiques
WO2007056159A3 (fr) Derives d'hydrazone et utilisations de ceux-ci
WO2004014868A8 (fr) Derives de pyrimidine 2,4-diones, utilises comme inhibiteurs de metalloproteinase matricielle
WO2008105526A1 (fr) Composé macrocyclique
DE602004026903D1 (de) P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766409

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766409

Country of ref document: EP

Kind code of ref document: A2